MIM1

MIM1 is a selective small molecule inhibitor of **myeloid cell leukemia-1 (Mcl-1)**, an anti-apoptotic member of the Bcl-2 protein family. As a substituted pyrogallol derivative, MIM1 was discovered via high-throughput screening for its ability to bind selectively to Mcl-1, with an IC50 of approximately 4.8–4.78 μM. MIM1 disrupts Mcl-1-dependent survival pathways, inducing Bax/Bak-dependent apoptosis in leukemia and melanoma cell lines, causing mitochondrial membrane breakdown, glutathione depletion, and DNA fragmentation. It displays cytotoxic activity mainly against Mcl-1-dependent cancer cells and can potentiate the action of other antitumor agents, such as dacarbazine, through enhanced cell cycle arrest and apoptosis. MIM1 is considered a tool compound for preclinical evaluation of Mcl-1 targeting in cancer and has not been developed as a marketed pharmaceutical.